| Literature DB >> 20635633 |
Rashidul Haque1, Tanvir Ahmed, M A Wahed, Dinesh Mondal, A S M Hamidur Rahman, M John Albert.
Abstract
Despite the national vitamin A and antihelminthic prophylaxis programmes, both intestinal geohelminths and subclinical vitamin A deficiency continue to be prevalent among children in developing countries. Studies on potential synergistic effects of vitamin A supplementation and deworming on retinol status have inconsistent results. The purpose of the present study was to investigate the impacts of low-dose beta-carotene supplementation and antihelminthic therapy on serum retinol and beta-carotene concentrations in preschool children of Bangladesh. Two hundred and forty-four children, known to be infected with Ascaris lumbricoides, were randomized into four treatment groups: I-IV. Group I and II received two oral doses of 400 mg of albendazole each, the first dose at baseline and the second dose after four months; Group III and IV received placebo in place of albendazole. In addition, Group I and III received 1.2 mg of beta-carotene powder in capsule daily for six months, and Group II and IV received placebo in place of beta-carotene. Serum retinol and beta-carotene levels were measured before and after six months of the interventions. Serum retinol and beta-carotene increased significantly in Group I where both antihelminthic therapy and daily beta-carotene supplementation were given (p<0.05 and p<0.001 respectively). Antihelminthic therapy alone only improved serum beta-carotene concentration (p<0.0001). Low-dose beta-carotene supplementation, along with an antihelminthic therapy, synergistically improved vitamin A status. This finding has public-health implications for improving vitamin A status of children in developing countries.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20635633 PMCID: PMC2980887 DOI: 10.3329/jhpn.v28i3.5549
Source DB: PubMed Journal: J Health Popul Nutr ISSN: 1606-0997 Impact factor: 2.000
Characteristics of study children infected with A. lumbricoides at baseline*
| Parameter | Treatment group | |||
|---|---|---|---|---|
| Group I (n=52) | Group II (n=55) | Group III (n=58) | Group IV (n=56) | |
| Albendazole+β-carotene | Albendazole+ placebo | β-carotene+ placebo | Placebo+ placebo | |
| Age (months) | 45.9±1.5 | 43.9±1.5 | 46.2±1.4 | 43.8±1.3 |
| Gender, % boys | 52 | 62 | 57 | 48 |
| Weight (kg) | 12.2±0.3 | 12.3±0.3 | 12.4±0.3 | 12.4±0.3 |
| Height (cm) | 90.9±1.1 | 90.9±1.2 | 91.4±1.0 | 91.6±1.3 |
| Height-for-age (%) | 90.4±0.9 | 91.7±0.9 | 90.6±0.9 | 91.9±1.0 |
| Weight-for-age (%) | 76.3±1.4 | 78.4±1.5 | 78.1±1.6 | 79.2±1.5 |
| Weight-for-height (%) | 90.6±0.8 | 87.7±3.5 | 92.6±1.3 | 91.5±0.9 |
| 3853±340 | 4923±551 | 4853±473 | 4689±426 | |
| 96.1 | 96.3 | 98.2 | 96.4 | |
*Mean±SEM;
†Values are in relation to the World Health Organization standards (28);
‡Eggs per g of stool sample;
SEM=Standard error of the mean
Drug efficacy and changes in helminthic infections in stools of children*
| Helminth | Treatment group | |||
|---|---|---|---|---|
| Group I (n=52) | Group II (n=55) | Group III (n=58) | Group IV (n=56) | |
| Albendazole+ β-carotene | Albendazole+ placebo | β-carotene+ placebo | Placebo+ placebo | |
| Baseline stool examination | ||||
| | 3854±340 | 4923±551 | 4853±474 | 4689±426 |
| | 1082±159 | 1311±188 | 1310±136 | 1571±194 |
| Final stool examination | ||||
| | 1±1 | 19±12 | 4332±657 | 4525±738 |
| | 83±41 | 205±63 | 880±125 | 1052±201 |
| Children with eggs at final examination | ||||
| | 1 | 3 | 52 | 45 |
| | 10 | 18 | 54 | 49 |
| Cure rate (%) | ||||
| | 98.1 | 94.5 | 10.3 | 19.6 |
| | 80.8 | 67.3 | 6.9 | 12.5 |
*The first stool examination was done at the time of initial subject recruitment, and the final examination was done after 4 months before the second antihelminthic drug and placebo were given;
†Mean±SEM;
‡Calculated as the percentage of those with no A. lumbricoides and T. trichiura eggs observed in the stool compared to the total number of children examined in the group;
SEM=Standard error of the mean
Fig.Effect of antihelminthic therapy with albendazole and daily low-dose β-carotene supplementation on serum retinol and β-carotene levels